Key points are not available for this paper at this time.
Abstract Recently, MDS with mutated SF3B1 and blast count 5% was not. In conclusion, SF3B1 mut MDS has a favorable prognosis independent of blast count if karyotype and RUNX1 mutations are considered.
Huber et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: